Área terapéutica:
Enfermedades Infecciosas

Publicaciones de Enfermedades Infecciosas

Año publicación Título Código Acrónimo Tipo Área
2026 Subphenotype- and complication-guided adjunctive fosfomycin versus standard monotherapy in Staphylococcus aureus bacteraemia: pooled analysis of two randomised trials 19016 SAFO RESULTADOS Enfermedades Infecciosas
2026 Subphenotype- and complication-guided adjunctive fosfomycin versus standard monotherapy in Staphylococcus aureus bacteraemia: pooled analysis of two randomised trials 14007 BACSARM RESULTADOS Enfermedades Infecciosas
2025 Effectiveness of oral step-down therapy and early oral switch for bloodstream infections caused by Enterobacterales: A post hoc emulation trial of the SIMPLIFY trial 16.001 SIMPLIFY RESULTADOS Enfermedades Infecciosas
2023 Evaluation of the effectiveness and safety of oral vancomycin versus placebo in the prevention of recurrence of Clostridioides difficile infection in patients under systemic antibiotic therapy: a phase III, randomised, double-blind clinical trial. 19.010 PREVAN PROTOCOLO Enfermedades Infecciosas
2023 Antibiotic use and outcome in patients with negative blood cultures, a new target population for antimicrobial stewardship interventions: a prospective multicentre cohort (NO-BACT) 18.010 NO_BACT RESULTADOS Enfermedades Infecciosas
2026 Randomized double-blind clinical trial evaluating the effectiveness and safety of secondary prophylaxis with oral vancomycin versus placebo in the prevention of recurrence of clostridioides difficile infection in patients receiving systemic antibiotic therapy (PREVAN trial)  19.010 PREVAN RESULTADOS Enfermedades Infecciosas
2024 Eficacia de la infusión extendida de los antibióticos B-lactámicos en el tratamiento de la neutropenia febril en los pacientes hematológicos 19.017 BEATLE RESULTADOS Enfermedades Infecciosas
2024 Efficacy and safety of a structured de-escalation from antipseudomonal β-lactams in bloodstream infections due to Enterobacterales (SIMPLIFY): an open-label, multicentre, randomised trial 16.001 SIMPLIFY RESULTADOS Enfermedades Infecciosas
2023 Efficacy and safety of different antimicrobial DURATions for the treatment of Infections associated with Osteosynthesis Material implanted after long bone fractures (DURATIOM): Protocol for a randomized, pragmatic trial 21.012 DURATIOM PROTOCOLO Enfermedades Infecciosas
2023 Randomised, open-label, non-inferiority clinical trial on the efficacy and safety of a 7-day vs 14-day course of antibiotic treatment for uncomplicated enterococcal bacteraemia: the INTENSE trial protocol 21.032 INTENSE PROTOCOLO Enfermedades Infecciosas
2023 Short-course antibiotic regimen compared to conventional antibiotic treatment for gram-positive cocci infective endocarditis: randomized clinical trial (SATIE) 20.006 SATIE PROTOCOLO Enfermedades Infecciosas
2023 Cloxacillin plus fosfomycin versus cloxacillin alone for methicillin-susceptible Staphylococcus aureus bacteremia: a randomized trial 19.016 SAFO RESULTADOS Enfermedades Infecciosas
2022 Double-blind placebo-controlled randomized clinical trial to assess the efficacy of montelukast in mild to moderate respiratory symptoms of patients with long COVID: E-SPERANZA COVID Project study protocol 21.040 E-SPERANZA COVID PROTOCOLO Enfermedades Infecciosas
2022 Early Use of Sarilumab in Patients Hospitalized with COVID-19 Pneumonia and Features of Systemic Inflammation: the SARICOR Randomized Clinical Trial 20.019 SARICOR RESULTADOS Enfermedades Infecciosas
2022 Study protocol for a randomized clinical trial to assess 7 versus 14-days of treatment for Pseudomonas aeruginosa bloodstream infections (SHORTEN-2 trial).  21.028 SHORTEN II PROTOCOLO Enfermedades Infecciosas
2022 Seven-versus 14-day course of antibiotics for the treatment of bloodstream infections by Enterobacterales: a randomized, controlled trial  15.011 SHORTEN I RESULTADOS Enfermedades Infecciosas
2022 Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections A Randomized Clinical Trial 14.005 FOREST RESULTADOS Enfermedades Infecciosas
2021 Clinical effectiveness and bacteriological eradication of three different Short-COurse antibiotic regimens and single-dose fosfomycin for uncomplicated lower Urinary Tract infections in adult women (SCOUT study): study protocol for a randomised clinical trial 21.026 SCOUT PROTOCOLO Enfermedades Infecciosas
2021 Vaccination adjuvated against hepatitis B in Spanish National Healthcare System (SNS) workers typed as non-responders to conventional vaccines 17.027 VACANTIB RESULTADOS Enfermedades Infecciosas
2021 Temocillin versus meropenem for the targeted treatment of bacteraemia due to third-generation cephalosporin-resistant Enterobacterales (ASTARTÉ): protocol for a randomised, pragmatic trial 20.004 ASTARTE PROTOCOLO Enfermedades Infecciosas
2020 Efficacy and safety of early treatment with sarilumab in hospitalised adults with COVID-19 presenting cytokine release syndrome (SARICOR STUDY): protocol of a phase II, open-label, randomised, multicentre, controlled clinical trial 20.019 SARICOR PROTOCOLO Enfermedades Infecciosas
2020 Randomised multicentre clinical trial to evaluate voriconazole pre-emptive genotyping strategy in patients with risk of aspergillosis: vorigenipharm study protocol 19.002 VORIGEPHARM PROTOCOLO Enfermedades Infecciosas
2019 Effectiveness of antitussives, anticholinergics or honey versus usual care in adults with uncomplicated acute bronchitis: a study protocol of an open randomised clinical trial in primary care 17029 AB4T PROTOCOLO Enfermedades Infecciosas
2019 Opportunities for antibiotic optimisation and outcome improvement in patients with negative blood cultures: study protocol for a cluster-randomised crossover trial, the NO-BACTstudy 18.010 NO_BACT PROTOCOLO Enfermedades Infecciosas
2018 Population pharmacokinetics and pharmacodynamics of fosfomycin in non-critically ill patients with bacteremic urinary infection caused by multidrug-resistant Escherichia coli 14.005 FOREST RESULTADOS Enfermedades Infecciosas
2018 Efficacy and safety of the combination of reduced duration prophylaxis followed by immuno-guided prophylaxis to prevent cytomegalovirus disease in lung transplant recipients (CYTOCOR STUDY): an open-label, randomised, non-inferiority clinical trial 18.008 CYTOCOR PROTOCOLO Enfermedades Infecciosas
2017 Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial 15.010 HOW LONG RESULTADOS Enfermedades Infecciosas
2017 Targeted simplification versus antipseudomonal broad-spectrum betalactams in patients with bloodstream infections due to Enterobacteriaceae (SIMPLIFY): a study protocol for a multicentre, open-label, phase III randomised, controlled, non-inferiority clinical trial 16.001 SIMPLIFY PROTOCOLO Enfermedades Infecciosas